Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863528 | 1.00 | TSHR (0.64) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL50994 | 0.90 | TSHR (0.54) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| Benzene SCHEMBL27561238 | 0.88 | L3MBTL1 (0.59) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL2598194 | 0.88 | L3MBTL1 (0.59) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL1612393 | 0.88 | TSHR (0.51) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL3803733 | 0.87 | TSHR (0.58) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL11398188 | 0.87 | TDP1 (0.56) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL4406921 | 0.86 | TSHR (0.50) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL9048711 | 0.86 | L3MBTL1 (0.58) | TSHRTDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL5469003 | 0.86 | TSHR (0.50) | TSHRTDP1L3MBTL1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1664027-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005021532-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0825187-A1 | Condensed pyridazinyl guanidines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997047589-A1 | AMINOPHTHALIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-18 | — | — | WO | disclosed |
| EP-0133310-B1 | IMIDAZOLIDINONES, AND IMIDAZOLIDINETHIONES, PROCESS FOR THE PREPARATION THEREOF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4608079-A | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1986-08-26 | — | — | US | disclosed |
| US-4554013-A | Herbicidal imidazolinyl naphthoic acids | AMERICAN CYANAMID COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
| EP-0133311-A2 | Substituted imidazolinyl benzoic acids, esters and salts and use thereof as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| EP-0133310-A1 | Imidazolidinones, and imidazolidinethiones, process for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | TSHR 1383/4885TDP1 3540/4885L3MBTL1 1537/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | TSHR 101/4885TDP1 2393/4885L3MBTL1 1747/4885 |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | VHL, DPYD, UGT1A1 | TSHR 4786/4885TDP1 955/4885L3MBTL1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.